Recent advances in the management of cryptococcal meningitis in patients with AIDS

Clinical Infectious Diseases

Volumn 22, Issue SUPPL. 2, 1996, Pages

  Powderly, William G ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Clinical Trials Unit   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CD4 ANTIGEN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; TRIAZOLE DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANDIDA; CLINICAL TRIAL; CONFERENCE PAPER; CRYPTOCOCCOSIS; DECISION MAKING; FUNGAL MENINGITIS; HUMAN; INFECTION PREVENTION; META ANALYSIS; PRIORITY JOURNAL; PROPHYLAXIS; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

EID: 0030057838     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/22.supplement_2.s119     Document Type: Conference Paper

References (32)

1. Powderly WG. Cryptococcal meningitis and AIDS. Clin Infect Dis 1993;17:837-42.
2. Stern JJ, Hartmen BJ, Sharkey P, et al. Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients. Am J Med 1988;85:477-80.
3. Dupont B, Hilmarsdottir I, Datry A, et al. Cryptococcal meningitis in AIDS patients - a pilot study of fluconazole therapy in 52 patients. In: Vanden Bossche H, Mackenzie DWR, Cauwenbergh G, van Cutsem J, Drouhet E, Dupont B, eds. Mycosis in AIDS patients. New York: Plenum Press, 1990:287-304.
4. Denning DW, Tucker RM, Hanson LH, Hamilton JR, Stevens DA. Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Arch Intern Med 1989;149:2301-8.
5. Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992;326:83-9.
6. Larsen RA, Leal AE, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial. Ann Intern Med 1990;113:183-7.
7. de Gans J, Portegies P, Tiessens G, et al. Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis. AIDS 1992;6:185-90.
8. Moskovitz BL, Wiesinger B, the Cryptococcal Meningitis Research Group. Randomized comparative trial of itraconazole and fluconazole for treatment of AIDS-related cryptococcal meningitis. In: Abstracts of the 1st National Conference on Human Retroviruses. Washington, DC: American Society for Microbiology, 1994:61.
9. Van der Horst C, the NIAID AIDS Clinical Trials Group and Mycoses Study Group. Randomized double blind comparison of amphotericin B (AMB) plus flucytosine to AMB alone (step 1) followed by a comparison of fluconazole to itraconazole (step 2) in the treatment of acute cryptococcal meningitis in patients with AIDS. Part 1 [abstract no I216]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995.
10. de Lalla F, Pellizzer G, Vaglia A, et al. Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: reliability of relatively high doses administered over a relatively short period. Clin Infect Dis 1995;20:263-6.
11. Coker RJ, Viviani M, Gazzarxd BG, et al. Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS 1993;7:829-35.
12. Berry AJ, Rinaldi MG, Graybill JR. Use of high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS. Antimicrob Agents Chemother 1992;36:690-2.
13. Haubrich RH, Haghighat D, Bozzette SA, Tilles J, McCutchan JA, the California Collaborative Treatment Group. High-dose fluconazole for treatment of cryptococcal disease in patients with human immunodeficiency virus infection. J Infect Dis 1994;170:238-42.
14. Larsen RA, Bozzette SA, Jones BE, et al. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1994;19:741-5.
15. Bozzette SA, Larsen RA, Chiu J, et al. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. N Engl J Med 1991;324:580-4.
16. Powderly WG, Saag MS, Cloud GA, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992;326:793-8.
17. Saag MS, the NIAID Mycoses Study Group. Comparison of fluconazole versus itraconazole as maintenance therapy of AIDS-associated cryptococcal meningitis [abstract no I218]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995.
18. Denning DW, Armstrong RW, Lewis BH, Stevens DA. Elevated cerebrospinal fluid pressures in patients with cryptococcal meningitis and acquired immunodeficiency syndrome. Am J Med 1991;91:267-72.
19. Johnston SRD, Corbett EL, Foster O, Ash S, Cohen J. Raised intracranial pressure and visual complications in AIDS patients with cryptococcal meningitis. J Infect 1992;24:185-9.
20. Malessa R, Krams M, Hengge U, et al. Elevation of intracranial pressure in acute AIDS-related cryptococcal meningitis. Clin Investig 1994;72:1020-6.
21. Currie BP, Feundlich LF, Casedevall A. Restriction fragment length polymorphism analysis of Cryptococcus neoformans isolates from environmental (pigeon excreta) and clinical sources in New York City. J Clin Microbiol 1994;32:1188-92.
22. Nightingale SD, Cal SX, Peterson DM, et al. Primary prophylaxis with fluconazole against systemic fungal infections in HIV-positive patients. AIDS 1992;6:191-4.
23. Powderly WG, Finkelstein DM, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995;332:700-5.
24. Quagliarello VJ, Viscoli C, Horwitz RI. Primary prevention of cryptococcal meningitis by fluconazole in HIV-infected patients. Lancet 1995;345:548-52.
25. McNeil JI, Kan VL. Decline in the incidence of cryptococcosis among HIV-infected patients [letter]. J Acquir Immune Defic Syndr 1995; 9:206-8.
26. Ampel NM, Dols CL, Galgiani JN. Coccidioidomycosis during human immunodeficiency virus infection: results of a prospective study in a coccidioidal endemic area. Am J Med 1993;94:235-40.
27. Wheat LJ, Connolly-Stringfield P, Baker RL, et al. Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature. Medicine (Baltimore) 1990;69:361-74.
28. Wheat LJ, Mawhinney S, Hafner R, et al. Fluconazole treatment for histoplasmosis in AIDS: prospective multicenter noncomparative trial [abstract no. I233]. In: Program and abstracts of the 34rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando, FL). Washington, DC: American Society for Microbiology, 1994,
29. Narang PK, Trapnell CB, Schoenfelder JR, Lavelle JP, Bianchine JR. Fluconazole and enhanced effect of rifabutin prophylaxis [letter]. N Engl J Med 1994;330:1316-7.
30. Powderly WG. Resistant candidiasis. AIDS Res Hum Retroviruses 1994;10:925-9.
31. Johnson EM, Warnock DW, Luker J, Porter SR, Scully C. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. J Antimicrob Chemother 1995;35:103-14.
32. USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: disease-specific recommendations. Clin Infect Dis 1995;21(suppl 1):S32-43.